At a glance
ClinicalIndex Comparison RecordPhase 2Completed
Drug / intervention
VRC-HIVDNA009-00-VPbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IB Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA009-00-VP, Administered at 2 Different Dosing Schedules, in HIV-1-Uninfected Adult Participants
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Nov 5, 2003·Updated Oct 14, 2021
In Brief
A Phase 2 clinical trial evaluating VRC-HIVDNA009-00-VP for HIV Infections. Completed, across 14 sites.
Detailed Summary
The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVDNA009-00-VP, in HIV uninfected participants. Two different doses of the vaccine will be tested.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2003
Enrollment StartDec 2003
Study CompletionOct 2005
TodayJul 2026
First PostedNov 5, 2003
Enrollment StartDec 1, 2003
Study CompletionOct 1, 2005
TodayJul 2, 2026
Posted 22.7 years ago
Interventions
VRC-HIVDNA009-00-VPbiological